Literature DB >> 30004115

LDL-Cholesterol Is Not the Only Clinically Relevant Biomarker for Coronary Artery Disease or Acute Coronary Syndrome.

Patrick A Field1, Ramachandran S Vasan1,2.   

Abstract

Coronary artery disease (CAD) is a progressive disorder and its risk is best determined using multiple biomarkers and risk factors. Many novel biomarkers have been shown to improve cardiovascular disease risk beyond that of the traditional risk factors, including polygenic risk scores, small very low-density lipoprotein (VLDL), ApoB, triglycerides (TG), non-HDL-c, lipoprotein (a) (Lp(a)), coronary calcium scores, C-reactive protein (CRP), B-type natriuretic peptide (BNP), troponins, and many other novel biomarkers that have been measured using high throughput assays.
© 2018 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30004115      PMCID： PMC6097909          DOI： 10.1002/cpt.1126

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  9 in total

1.  2013 ACC/AHA guideline on the assessment of cardiovascular risk.

Authors:  Bruce Andrus; Diane Lacaille
Journal:  J Am Coll Cardiol       Date:  2014-04-23       Impact factor: 24.094

2.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

3.  Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease.

Authors:  Peter Ganz; Bettina Heidecker; Kristian Hveem; Christian Jonasson; Shintaro Kato; Mark R Segal; David G Sterling; Stephen A Williams
Journal:  JAMA       Date:  2016-06-21       Impact factor: 56.272

4.  Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study.

Authors:  Raimund Erbel; Stefan Möhlenkamp; Susanne Moebus; Axel Schmermund; Nils Lehmann; Andreas Stang; Nico Dragano; Dietrich Grönemeyer; Rainer Seibel; Hagen Kälsch; Martina Bröcker-Preuss; Klaus Mann; Johannes Siegrist; Karl-Heinz Jöckel
Journal:  J Am Coll Cardiol       Date:  2010-10-19       Impact factor: 24.094

Review 5.  How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL.

Authors:  Maurizio Averna; Erik Stroes
Journal:  Atheroscler Suppl       Date:  2017-04       Impact factor: 3.235

Review 6.  B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies.

Authors:  Emanuele Di Angelantonio; Rajiv Chowdhury; Nadeem Sarwar; Kausik K Ray; Reeta Gobin; Danish Saleheen; Alexander Thompson; Vilmundur Gudnason; Naveed Sattar; John Danesh
Journal:  Circulation       Date:  2009-11-16       Impact factor: 29.690

7.  Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.

Authors:  J L Mega; N O Stitziel; S Kathiresan; M S Sabatine; J G Smith; D I Chasman; M Caulfield; J J Devlin; F Nordio; C Hyde; C P Cannon; F Sacks; N Poulter; P Sever; P M Ridker; E Braunwald; O Melander
Journal:  Lancet       Date:  2015-03-04       Impact factor: 79.321

8.  Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium.

Authors:  Stefan Blankenberg; Veikko Salomaa; Nataliya Makarova; Francisco Ojeda; Philipp Wild; Karl J Lackner; Torben Jørgensen; Barbara Thorand; Annette Peters; Matthias Nauck; Astrid Petersmann; Erkki Vartiainen; Giovanni Veronesi; Paolo Brambilla; Simona Costanzo; Licia Iacoviello; Gerard Linden; John Yarnell; Christopher C Patterson; Brendan M Everett; Paul M Ridker; Jukka Kontto; Renate B Schnabel; Wolfgang Koenig; Frank Kee; Tanja Zeller; Kari Kuulasmaa
Journal:  Eur Heart J       Date:  2016-05-12       Impact factor: 29.983

9.  Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.

Authors:  Patrick R Lawler; Akintunde O Akinkuolie; Audrey Y Chu; Svati H Shah; William E Kraus; Damian Craig; Latha Padmanabhan; Robert J Glynn; Paul M Ridker; Daniel I Chasman; Samia Mora
Journal:  J Am Heart Assoc       Date:  2017-07-21       Impact factor: 5.501
  9 in total
  3 in total

1.  Correlations between Body Mass Index, Plasma High-Sensitivity C-Reactive Protein and Lipids in Patients with Schizophrenia.

Authors:  Ted Boozalis; Sridevi Devaraj; Olaoluwa O Okusaga
Journal:  Psychiatr Q       Date:  2019-03

2.  Serological Evidence of Hepatitis B and E and Dengue Coinfection in Chadian Patients and Impact on Lipidemia Profile.

Authors:  Alexandre Kanga Djasrabe; Borris Rosnay Tietcheu Galani; Moussa Mahamat Ali; Fissou Henry Yandai; Bessimbaye Nadlaou; Mayann Habkreo; Nicolas Yanou Njintang
Journal:  Int J Hepatol       Date:  2022-09-16

3.  The Effect of Three Mediterranean Diets on Remnant Cholesterol and Non-Alcoholic Fatty Liver Disease: A Secondary Analysis.

Authors:  Angelo Campanella; Palma A Iacovazzi; Giovanni Misciagna; Caterina Bonfiglio; Antonella Mirizzi; Isabella Franco; Antonella Bianco; Paolo Sorino; Maria G Caruso; Anna M Cisternino; Claudia Buongiorno; Rosalba Liuzzi; Alberto R Osella
Journal:  Nutrients       Date:  2020-06-04       Impact factor: 5.717
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.